Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/PRX-08066> ?p ?o }
Showing triples 1 to 60 of
60
with 100 triples per page.
- PRX-08066 abstract "PRX-08066 is a drug discovered and developed by Predix (later Epix) Pharmaceuticals [Dale S. Dhanoa et al. Patent US 7,030,240 B2], which acts as a potent and selective antagonist at the serotonin 5-HT2B receptor, with a 5-HT2B binding affinity (Ki) of 3.4nM, and high selectivity over the closely related 5-HT2A and 5-HT2C receptors and other receptor targets. PRX-08066 and other selective 5-HT2B antagonists are being researched for the treatment of pulmonary arterial hypertension, following the discovery that the potent 5-HT2B agonist norfenfluramine produces pulmonary arterial hypertension and subsequent heart valve damage. In animal studies, PRX-08066 has been found to reduce several key indicators of pulmonary arterial hypertension and improved cardiac output, with similar efficacy to established drugs for this condition such as bosentan, sildenafil, beraprost and iloprost. It is also being researched for potential anti-cancer applications, due to its ability to inhibit fibroblast activation.".
- PRX-08066 iupacName "5-((4-(6-chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile".
- PRX-08066 pubchem "11502243".
- PRX-08066 thumbnail PRX-08066_structure.png?width=300.
- PRX-08066 wikiPageID "29732054".
- PRX-08066 wikiPageLength "3302".
- PRX-08066 wikiPageOutDegree "15".
- PRX-08066 wikiPageRevisionID "592867731".
- PRX-08066 wikiPageWikiLink 5-HT2A_receptor.
- PRX-08066 wikiPageWikiLink 5-HT2B_receptor.
- PRX-08066 wikiPageWikiLink 5-HT2C_receptor.
- PRX-08066 wikiPageWikiLink Beraprost.
- PRX-08066 wikiPageWikiLink Bosentan.
- PRX-08066 wikiPageWikiLink Category:5-HT2B_antagonists.
- PRX-08066 wikiPageWikiLink Dissociation_constant.
- PRX-08066 wikiPageWikiLink Fibroblast.
- PRX-08066 wikiPageWikiLink Iloprost.
- PRX-08066 wikiPageWikiLink Norfenfluramine.
- PRX-08066 wikiPageWikiLink Pulmonary_hypertension.
- PRX-08066 wikiPageWikiLink Receptor_(biochemistry).
- PRX-08066 wikiPageWikiLink Receptor_antagonist.
- PRX-08066 wikiPageWikiLink Serotonin.
- PRX-08066 wikiPageWikiLink Sildenafil.
- PRX-08066 wikiPageWikiLinkText "PRX-08066".
- PRX-08066 c "19".
- PRX-08066 chemspiderid "9677045".
- PRX-08066 cl "1".
- PRX-08066 f "1".
- PRX-08066 h "17".
- PRX-08066 iupacName "5".
- PRX-08066 molecularWeight "401.887".
- PRX-08066 n "5".
- PRX-08066 pubchem "11502243".
- PRX-08066 s "1".
- PRX-08066 smiles "s3c2ncncNC4CCNCccc1C#N".
- PRX-08066 width "220".
- PRX-08066 wikiPageUsesTemplate Template:Drugbox.
- PRX-08066 wikiPageUsesTemplate Template:Nervous-system-drug-stub.
- PRX-08066 wikiPageUsesTemplate Template:Reflist.
- PRX-08066 wikiPageUsesTemplate Template:Serotonergics.
- PRX-08066 subject Category:5-HT2B_antagonists.
- PRX-08066 hypernym Drug.
- PRX-08066 type ChemicalSubstance.
- PRX-08066 type Drug.
- PRX-08066 type Antagonist.
- PRX-08066 type Chemical.
- PRX-08066 type Drug.
- PRX-08066 type ChemicalObject.
- PRX-08066 type Thing.
- PRX-08066 type Q8386.
- PRX-08066 comment "PRX-08066 is a drug discovered and developed by Predix (later Epix) Pharmaceuticals [Dale S. Dhanoa et al. Patent US 7,030,240 B2], which acts as a potent and selective antagonist at the serotonin 5-HT2B receptor, with a 5-HT2B binding affinity (Ki) of 3.4nM, and high selectivity over the closely related 5-HT2A and 5-HT2C receptors and other receptor targets.".
- PRX-08066 label "PRX-08066".
- PRX-08066 sameAs Q44793.
- PRX-08066 sameAs m.0fq33lc.
- PRX-08066 sameAs PRX-08066.
- PRX-08066 sameAs PRX-08066.
- PRX-08066 sameAs Q44793.
- PRX-08066 wasDerivedFrom PRX-08066?oldid=592867731.
- PRX-08066 depiction PRX-08066_structure.png.
- PRX-08066 isPrimaryTopicOf PRX-08066.